Table 2. Subgroup analysis of the effects of glucagon-like peptide-1 receptor agonists on visceral adipose tissue and hepatic fat content.
| Grouping characteristics | Study number | VAT | I2 between groups | P | Study number | HFC(%) | I2 between groups | P |
|---|---|---|---|---|---|---|---|---|
| SMD(95%CI) | WMD(95%CI) | |||||||
| Follow-up time | ||||||||
| >24weeks | 12 | -0.77(-1.17,-0.37) | 35.40% | 0.21 | 6 | -3.30(-4.65,-1.96) | 0% | 0.73 |
| ≤24weeks | 12 | -0.59(-0.83,-0.36) | 9 | -2.90(-4.16,-2.02) | ||||
| GLP-1Ras type | ||||||||
| Liraglutide | 17 | -0.68(-1.00,-0.36) | 63.70% | 0.06 | 9 | -2.71(-4.59,-0.83) | 0% | 0.82 |
| Exenatide | 6 | -0.46(-0.70,-0.21) | 5 | -3.42(-4.77,-2.06) | ||||
| Other GLP-1Ra | 1 | -0.16(-0.46,-0.13) | 1 | -3.50(-6.56,-0.44) | ||||
| Baseline BMI | ||||||||
| >30 kg/m2 | 15 | -0.60(-0.93,-0.26) | 14.50% | 0.31 | 8 | -1.99(-3.64,-0.33) | 46.20% | 0.16 |
| 25–30 kg/m2 | 6 | -0.74(-1.19,-0.30) | 5 | -3.96(-5.83,-2.09) | ||||
| <25kg/m2 | 2 | -0.30(-0.69,-0.09) | 2 | -3.88(-5.13,-2.64) | ||||
| Age | ||||||||
| >50 years old | 16 | -0.46(-0.71,-0.20) | 11.50% | 0.32 | 10 | -3.05(-4.29,-1.81) | 0% | 0.8 |
| 40–50 years old | 4 | -0.68(-0.93,-0.44) | 5 | -3.41(-5.96,-0.86) | ||||
| <40 years old | 2 | -2.09(-5.76,1.57) | ||||||
| Outcome Measures Method | ||||||||
| Magnetic resonance class | 15 | -0.67(-1.04,-0.30) | 38.50% | 0.18 | 14 | -2.99(-4.04,-1.94) | 54.90% | 0.14 |
| CT | 5 | -0.47(-0.71,-0.23) | ||||||
| DXA | 3 | -0.37(-0.75,0.01) | ||||||
| Other measurement methods | 1 | -1.04(-1.58,-0.50) | 1 | -8.54(-15.77,-1.31) |